Scarica l'app Stockscreener
13.74
4.33%
0.57
Dopo l'orario di chiusura:
13.74
Precedente Chiudi:
$13.17
Aprire:
$13.33
Volume 24 ore:
651.59K
Relative Volume:
0.71
Capitalizzazione di mercato:
$1.62B
Reddito:
-
Utile/perdita netta:
$-151.09M
Rapporto P/E:
-8.8077
EPS:
-1.56
Flusso di cassa netto:
$-160.51M
1 W Prestazione:
+2.31%
1M Prestazione:
+2.46%
6M Prestazione:
-21.49%
1 anno Prestazione:
+56.67%
Intervallo 1D:
$13.20
$13.88
Intervallo di 1 settimana:
$12.74
$13.88
Portata 52W:
$8.46
$19.09
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Nome
Centessa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
44 7391 789784
Indirizzo
3RD FLOOR, ALTRINCHAM, CHESHIRE
Confronta CNTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
13.74 | 1.62B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-05-08 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-31 | Iniziato | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-19 | Iniziato | B. Riley Securities | Buy |
| 2024-07-18 | Iniziato | Oppenheimer | Outperform |
| 2023-11-15 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-10-26 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-06-21 | Iniziato | Evercore ISI | Outperform |
| 2023-06-12 | Iniziato | Guggenheim | Buy |
| 2023-03-17 | Iniziato | SVB Securities | Outperform |
| 2022-08-12 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-02-11 | Iniziato | Goldman | Neutral |
Mostra tutto
Centessa Pharmaceuticals Plc Adr Borsa (CNTA) Ultime notizie
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders - MarketScreener
Centessa Pharmaceuticals plc Announces Clearance of Investigational New Drug Application for ORX142 - MarketScreener
SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest - Quantisnow
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet - MSN
Centessa Pharmaceuticals Announces Executive Changes By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals Announces Executive Changes - Investing.com India
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 Net Loss $0.20 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 License and Other Revenue of $15M - marketscreener.com
Is Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) A Suitable Stock For New Investors Today? - Stocksregister
Ratios in Focus: Analyzing Centessa Pharmaceuticals plc ADR (CNTA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Investor’s Delight: Centessa Pharmaceuticals plc ADR (CNTA) Closes Weak at 13.50, Down -1.53 - DWinneX
Was Centessa Pharmaceuticals plc ADR (CNTA)’s session last reading good? - uspostnews.com
Top investors say Centessa Pharmaceuticals plc ADR (CNTA) ticks everything they need - Sete News
Investor’s Toolkit: Key Ratios for Assessing MSCI Inc (MSCI)’s Performance - DWinneX
Financial Metrics Check: Centessa Pharmaceuticals plc ADR (CNTA)’s Ratios for Trailing Twelve Months - DWinneX
Should investors be concerned about Centessa Pharmaceuticals plc ADR (CNTA)? - uspostnews.com
Parsons Corp (PSN) Shares Up Despite Recent Market Volatility - News Heater
Lantheus Holdings Inc [LNTH] Insider Activity: An Update for Investors - knoxdaily.com
Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target - MarketScreener
Centessa Pharmaceuticals chief business officer sells $163,386 in stock - Investing.com
Centessa Pharmaceuticals CEO sells shares worth $918,060 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CEO sells shares worth $918,060 - Investing.com India
Centessa Pharmaceuticals CAO sells shares worth $120,205 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CAO sells shares worth $120,205 - Investing.com India
Centessa Pharmaceuticals’ general counsel sells $98,697 in stock - Investing.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - Stocks Register
Ratios Revealed: Decoding Centessa Pharmaceuticals plc ADR (CNTA)’s Financial Health - The Dwinnex
Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight - GlobeNewswire Inc.
Centessa Pharmaceuticals officer sells shares worth $588,943 - Investing.com India
Aegon Ltd (AEG) looking to reclaim success with recent performance - SETE News
Adversity is less terrifying than hope: Wayfair Inc (W) - SETE News
Perhaps timely catching Autolus Therapeutics plc ADR (AUTL) would be a good idea - SETE News
Taking the lead: Centessa Pharmaceuticals plc ADR (CNTA) - SETE News
Centessa Pharmaceuticals plc ADR (CNTA) Volatility Hits 6.67%: What Good Investors Need To Be Aware Of - Stocks Register
RLI Corp’s (RLI) Stock: A Week-by-Week Analysis - The News Heater
Centessa Pharmaceuticals plc ADR (CNTA) Shares Up Despite Recent Market Volatility - The News Heater
Aon plc (AON) Stock: Evaluating the Market Performance - The News Heater
Qudian Inc ADR (QD) Stock: A Look at the Analyst Recommendations - The News Heater
Examining the Volatility of Costamare Inc’s (CMRE) Stock - The News Heater
Centessa Pharmaceuticals officer Tia Bush sells $185,406 in shares - Investing.com
Financial Fitness Check: Examining Magna International Inc (MGA)’s Key Ratios - The Dwinnex
Financial Metrics Exploration: Understanding Oncolytics Biotech, Inc (ONCY) Through Ratios - The Dwinnex
Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex
A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News
Centessa Pharmaceuticals chief business officer sells shares worth $193,429 - Investing.com India
Form N-CSR FIDELITY CONCORD STREET For: Nov 30 - StreetInsider.com
Centessa Pharmaceuticals general counsel Hussain Iqbal sells $91,740 in shares - Investing.com
Centessa Pharmaceuticals appoints new Chief Medical Officer - Investing.com
Centessa Pharmaceuticals' chief business officer sells shares worth $170,399 - Investing.com
Centessa Pharmaceuticals Plc Adr Azioni (CNTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Centessa Pharmaceuticals Plc Adr Azioni (CNTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Weinhoff Gregory M | Chief Business Officer |
Jun 25 '25 |
Sale |
13.86 |
10,000 |
138,642 |
122,279 |
| HUSSAIN IQBAL J | General Counsel |
Jun 24 '25 |
Option Exercise |
5.84 |
12,000 |
70,080 |
117,386 |
| HUSSAIN IQBAL J | General Counsel |
Jun 24 '25 |
Sale |
14.02 |
12,000 |
168,218 |
105,386 |
| Accardi Mario Alberto | President, Orexin Program |
Jun 24 '25 |
Option Exercise |
3.85 |
15,000 |
57,750 |
231,485 |
| Accardi Mario Alberto | President, Orexin Program |
Jun 24 '25 |
Sale |
14.00 |
15,000 |
210,000 |
216,485 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):